PMID- 21298865
OWN - NLM
STAT- MEDLINE
DCOM- 20110303
LR  - 20201209
IS  - 0368-2781 (Print)
IS  - 0368-2781 (Linking)
VI  - 63
IP  - 4
DP  - 2010 Aug
TI  - [Evaluation of target attainment rate of pazufloxacin mesilate using Monte Carlo 
      simulation method].
PG  - 319-25
AB  - We calculated achievement rates of target attainment of AUC/MIC using Monte Carlo 
      simulation (MCS). Two doses of pazufloxacin mesilate (PZFX) between q.d. and 
      b.i.d. were compared for each species of bacterium. Concentrations for AUC of 
      PZFX of 8 patients were measured at this hospital, and those from a phase I 
      clinical study (phase I, 6 healthy volunteers) were used. MICs of PZFX were 
      determined for each species of bacterium of respiratory organ origin (Pseudomonas 
      aeruginosa, Haemophilus influenzae, Streptococcus pneumoniae, and Klebsiella 
      pneumoniae). AUC per day of 500 mg b.i.d. used twice AUC (PZFX 500 mg x 2/day by 
      patient, PZFX 500 mg x 2/day by phase I). Target attainment of AUC/MIC was 
      AUC/MIC > or = 30 in S. pneumoniae and AUC/MIC > or = 125 in the other species of 
      bacteria (P. aeruginosa, H. influenzae, and K. pneumoniae). As a result, patients 
      showed an about 3 times higher AUC than the phase I subjects (67.9/21.9 
      microg/mL). In addition, the target attainment of AUC/MIC showed the highest rate 
      in PZFX 500 mg x 2/day in patients with each type of bacteria: H. influenzae 
      (98%), K. pneumoniae (89%), S. pneumoniae (66%), and P aeruginosa (41%). Target 
      attainment of AUC/MIC was H. influenzae (91%), K. pneumoniae (81%), P. aeruginosa 
      (5%), and S. pneumoniae (0%) in phase I. Therefore, the effectiveness of PZFX was 
      estimated to be low using the MCS method with the phase I data.
FAU - Abe, Noriuyuki
AU  - Abe N
AD  - Department of Clinical Pathology, Tenri Hospital.
FAU - Fukuda, Saori
AU  - Fukuda S
FAU - Nakamura, Akihiro
AU  - Nakamura A
FAU - Taguchi, Yosio
AU  - Taguchi Y
FAU - Matsuo, Shuji
AU  - Matsuo S
LA  - jpn
PT  - Journal Article
PL  - Japan
TA  - Jpn J Antibiot
JT  - The Japanese journal of antibiotics
JID - 0154402
RN  - 0 (Antitubercular Agents)
RN  - 0 (Fluoroquinolones)
RN  - 0 (Oxazines)
RN  - 4CZ1R38NDI (pazufloxacin)
SB  - IM
MH  - Adolescent
MH  - Antitubercular Agents/administration & dosage/pharmacokinetics/*pharmacology
MH  - Community-Acquired Infections/*microbiology
MH  - Drug Resistance, Bacterial
MH  - Fluoroquinolones/administration & dosage/pharmacokinetics/*pharmacology
MH  - Haemophilus influenzae/*drug effects/isolation & purification
MH  - Humans
MH  - Klebsiella pneumoniae/*drug effects/isolation & purification
MH  - *Monte Carlo Method
MH  - Oxazines/administration & dosage/pharmacokinetics/*pharmacology
MH  - Pneumonia, Bacterial/*microbiology
MH  - Pseudomonas aeruginosa/*drug effects/isolation & purification
MH  - Streptococcus pneumoniae/*drug effects/isolation & purification
MH  - Young Adult
EDAT- 2011/02/09 06:00
MHDA- 2011/03/04 06:00
CRDT- 2011/02/09 06:00
PHST- 2011/02/09 06:00 [entrez]
PHST- 2011/02/09 06:00 [pubmed]
PHST- 2011/03/04 06:00 [medline]
PST - ppublish
SO  - Jpn J Antibiot. 2010 Aug;63(4):319-25.